Indeed , pharma is still reeling from three damaging    in the last year , each one " yuge " —   and hugely negative .First , the decision of Pfizer to undertake a " tax inversion " exile to the United Kingdom .   From a strictly business point of view , Pfizer ’s relocation Pfizer .   It ’s perfectly obvious that the US corporate tax rate is not only too high , but also counterproductive from a revenue perspective .   